- Length of hospitalization reduced by more than 50% versus US
national average
- No complications or recurrence of bleeding seen during patient
treatments at University of California
Irvine
STOCKHOLM, Sept. 29, 2020 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced the presentation of clinical research at the 18th Annual
Meeting of the Neurocritical Care Society (NCS) that showed that
the company's IRRAflow system safely treats chronic subdural
hematomas while also decreasing complications, bleeding recurrence,
and length of hospitalization.
During the event that was held virtually, Dr. Jordan Davies from the University of California Irvine (UCI) Medical
Center presented a poster that concludes "Novel, continuous
irrigation and drainage of the subdural space following chronic
subdural hematoma evacuation is safe and shows decreased
recurrence, complications, and length of stay." The research
documents UCI's treatment of their initial 6 chronic subdural
hematoma patients using the IRRAflow system and shows that
these patients experienced no complications or bleeding recurrence
and were hospitalized for an average of 2.83 days, which is less
than half of the United States'
national average of 6 days.
The poster can be viewed at the following link:
https://cdn1.digitellinc.com/uploads/ncs/pages/f2507afcf423e7a7d18bd616bb1fdf1a.pdf.
Subdual hematomas are projected to become the most common
cranial neurosurgical condition among adults by the year 2030 in
the United
States1. IRRAflow's potential to
reduce complications and length of hospitalization could result in
significant overall cost reductions as the total patient population
continues to grow.
Additionally, Dr. Davies also presented a second clinical
research poster on IRRAflow during the event. This poster,
entitled, "Using net output to guide continuous irrigation and
drainage of the subdural space following surgical evacuation can
safely decrease hospital stay," outlines UCI's treatment approach
with IRRAflow and shows that higher rates of irrigation
earlier in patient treatment results in increased drainage of blood
and shorter overall treatment times.
This poster can be viewed at the following link:
https://cdn1.digitellinc.com/uploads/ncs/pages/f3f61e3b417f0a132a152872192c6b42.png.
"We are very pleased that the data generated from UCI's
experience with our IRRAflow system is being shared with the
scientific community to demonstrate that the positive effect of
irrigation does not need to end in the operating room," said
Will Martin, President and Chief
Commercial Officer of IRRAS. "This early data shows that
IRRAflow's ability to irrigate throughout the patient
treatment more thoroughly removes collected blood, which can result
in better patient outcomes, decreased length of hospitalization,
and reduced overall cost to the healthcare system. IRRAS and our
physician partners look forward to expanding upon this early data
with larger and more impactful data sets in the future."
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on September 29, 2020 at 10:00 (CET).
1) Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual
and projected incidence rates for chronic subdural hematomas in
United States Veterans
Administration and civilian populations. J Neurosurg.
2015;123(5):1209-1215.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-release-of-clinical-data-that-validates-safety-and-effectiveness-of-irraflow-system-,c3204416